sur VALNEVA (EPA:VLA)
Valneva Reports Half Year 2024 Financial Results and Provides Corporate Updates
Valneva SE has announced its financial results for the first half of 2024. Total revenues were €70.8 million, with product sales contributing €68.3 million, aligning with their full-year guidance. The company posted a net profit of €34.0 million, an improvement on the previous year's loss. Operating profit was €46.7 million, compared to a loss of €35.0 million in the first half of 2023.
Valneva's cash position stands at €131.4 million. The company expects a substantially lower cash burn in the second half of 2024, owing to the completion of its cost contributions for its Lyme disease program and an updated debt financing agreement.
The company confirmed its full-year financial guidance, projecting total revenues between €170 million and €190 million. They reported significant developments in their clinical pipeline, including an exclusive license for a Shigella vaccine candidate, additional marketing authorizations for their IXCHIQ® vaccine, and positive data from a Phase 3 adolescent study.
R. H.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de VALNEVA